ArticleFrontiers in oncology2025
Case Report: Giant cell lesions in the Maxillofacial region: diagnostic points and treatment strategies.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- β-Human Chorionic Gonadotropin-Secreting Giant Cell Tumor of Bone in the Mandible: Case Report and Comprehensive Literature Review.Head and neck pathology · 2026Review
- Giant cell reparative granuloma of the calcaneus in a 32-year-old man without recurrence at 7-year follow-up: a case report.Frontiers in surgery · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Giant cell-rich lesions in the maxillofacial region are relatively rare, and comprehensive clinical differential diagnostic protocols are currently lacking. This article aims to provide a reference for the clinical diagnosis and treatment of giant cell-rich lesions. Methods: This study investigates the distinguishing features of four types of giant cell-rich lesions in differential diagnosis and treatment: giant cell tumor of bone (GCT), aneurysmal bone cyst (ABC), tenosynovial giant cell tumor (TGCT), and giant cell reparative granuloma (GCRG). Results: Immunohistochemical (IHC) analysis reveals strong p63 positivity in the mononuclear stromal cells of GCT, but not in GCRG. The "fluid-fluid level" observed in magnetic resonance imaging (MRI) is a diagnostic indicator for ABC, reflecting variable signal intensities. TGCT is characterized by the presence of synovial monocytes, multinucleated giant cells, foam cells, and hemosiderin-laden cells. Conclusion: Accurate diagnosis requires a comprehensive evaluation of clinical, imaging, and pathological data. While complete resection is crucial for GCT to prevent recurrence and malignant transformation, GCRG typically responds well to curettage due to its benign nature. Early surgical intervention is essential for TGCT to control its aggressive progression and minimize complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.